Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.

You may also be interested in...



ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon

A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.

ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon

A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.

Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors

Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.

Table

View full table

Related Content

In Vivo
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Final ICH Guide Supports Nonclinical Development Of Gene Therapy Products

NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others

Canadian Action On Rare Disease Is A ‘Step Forward,’ Says Industry

Three Firms Sign Up With MPP For Long-Acting Cabotegravir

See All
UsernamePublicRestriction

Register

PS068466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By